Xilio Therapeutics, Inc.

NASDAQ:XLO

Biotechnology

Healthcare
$7.63 +5.14%

+$0.45 today

Market cap
$53.90M
Beta
-0.09
P/E (TTM)
-48.1
EPS (TTM)
-$0.19
52W Low $6.47High $12.74

Volume 0.01M

Average 0.05M

XLO Change in Working Capital

Cash absorbed or released by changes in receivables, inventory, payables, and other operating balances.

Xilio Therapeutics, Inc.NASDAQ: XLO

Change in Working Capital · Q1 FY2026 · quarter ended Mar 2026

Change in working capital turns negative

Q1 FY2026 change in working capital was -$12.07M, compared with $40.21M a year earlier. Trailing-twelve-month change in working capital was -$27.16M. Over 3 fiscal years it compounded at +132.3% a year.

Context

  • Change in working capital amounted to 57.4% of revenue in FY2025, down 443.6 pp from a year earlier.
  • Change in working capital increased in 1 of the last 3 fiscal years.

What to watch

Whether quarterly change in working capital holds near -$12.07M or moves back toward the trailing-twelve-month quarterly average of -$6.79M.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$12.07M-313.1% QoQ
Last fiscal yearDec 2025
$25.13M-20.9% YoY
LTMMar 2026
-$27.16M-182.7% YoY
Change in Working Capital past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-130.0%——
1 year-20.9%——
3-year CAGR+132.3%——
5-year CAGR——
10-year CAGR——

Change in Working Capital history

USD · from the cash flow

Latest · FY2025
25.13M USD
Year-over-year change
-20.9%

Change in Working Capital vs competitors

How XLO compares with its peers on the latest reported figures

  • XLO's LTM Mar 2026 change in working capital of $27.16M is the 2nd largest of the 4 companies compared; the peer median is $4.51M.
  • Its year-over-year change of -182.7% is the lowest of 4, against a peer median of +180.7%.
  • Change in working capital amounts to 50.8% of revenue for XLO, versus a peer median of 103.5%.
XLO Competitors Peer median
Change in Working Capital for XLO and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ATNMActinium Pharmaceuticals, Inc.LTM Jun 2026$36.31M +1643.8%—103.5%
XLOXilio Therapeutics, Inc.LTM Mar 2026$27.16M -182.7%+132.3%50.8%
OKUROnKure Therapeutics, Inc.LTM Mar 2026$4.51M -129.9%——
PDSBPDS Biotechnology CorporationLTM Mar 2026$3.26M +180.7%——
Peer median (excluding XLO) $4.51M+180.7%—103.5%

Competitors are the stored peer set for XLO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(75.8M)(88.22M)(76.4M)(58.24M)(35.04M)
Depreciation & Amortization1.5M1.85M1.9M1.64M1.54M
Deferred Income Tax222K0000
Stock-Based Compensation4.96M8.42M7.38M6.43M6.94M
Change in Working Capital(11.8M)2M(1.66M)31.78M25.13M
Accounts Receivables0000(5M)
Inventory00000
Accounts Payables(2.82M)485K(2.06M)1.53M152K
Other Working Capital(8.99M)1.52M405K30.26M29.97M
Other Non-Cash Items173K224K160K3K(3.56M)
Operating Cash Flow(80.75M)(75.72M)(68.62M)(18.38M)(4.99M)
Capital Expenditures(1.1M)(1.87M)(486K)(36K)(518K)
Acquisitions (Net)00000
Purchases of Investments00000
Sales of Investments00000
Other Investing Activities00000
Investing Cash Flow(1.1M)(1.87M)(486K)(36K)(518K)
Debt Repayment(110K)(85K)(6.75M)(3.38M)0
Common Stock Issued116.36M16K202K6.83M87.78M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities(467K)0025.75M0
Financing Cash Flow260.67M(69K)(6.55M)29.2M87.78M
Effect of Forex Changes0(9K)(25K)00
Net Change in Cash178.82M(77.67M)(75.68M)10.78M82.27M
Free Cash Flow(81.85M)(77.59M)(69.11M)(18.41M)(5.51M)

Xilio Therapeutics, Inc.

NASDAQ:XLO

Intrinsic Alpha fair value

Locked

Current Price

$7.63

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.